CER 2

Drug Profile

CER 2

Alternative Names: IE 7M

Latest Information Update: 07 Sep 2005

Price : $50

At a glance

  • Originator Cermol
  • Developer Dr. Willmar Schwabe Pharmaceuticals
  • Class Cardiovascular therapies
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cardiovascular disorders

Most Recent Events

  • 06 Sep 2005 Discontinued - Phase-I for Cardiovascular disorders in Germany (PO)
  • 19 Mar 2002 CER 2 is available for licensing [www.schwabe-forschung.de]
  • 19 Mar 2002 Phase-I clinical trials in Cardiovascular disorders in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top